Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index; none of the 1 sources its claims cite is checked for support yet.

Native Metabolomics Unveils Suomilide Analogs with Potent Trypsin Inhibitory Activity

Open access

Abstract

High Resolution Image Download MS PowerPoint Slide Cyanobacteria are well-known for their ability to produce a diverse array of serine protease inhibitors and thus are a promising source of pharmaceutical lead structures. Here, native metabolomics was employed with trypsin to rapidly screen whole cyanobacterial metabolomes and uncover new potent inhibitors. In combination with subsequent correlative LC-HR-MS/MS-based analysis, this led to the fast discovery of the well-characterized natural product family of suomilides from Nostoc sp. KVJ20 as highly potent trypsin inhibitors. Notably, two of the six putative binders were recognized as potential unknown analogs and thus were chosen for isolation and structural elucidation by means of 1D/2D NMR spectroscopy, Marfey’s analysis, and bioinformatic investigations. This resulted in the identification of new suomilides G and H ( 1 / 2 ), which were isolated together with the known congeners suomilide B ( 3 ) and D ( 4 ). We also demonstrated that all four isolated suomilides inhibit trypsin at low nanomolar to high picomolar concentrations in a competitive bioassay, confirming the exceptional potency of this growing compound family as protease inhibitors.

Overview

CoChat Summary

## TL;DR

Native metabolomics screening of eight cyanobacterial extracts identified *Nostoc* sp. KVJ20 as a source of six putative trypsin binders, leading to the isolation and structural elucidation of two new suomilides, G and H. All four isolated suomilides inhibited trypsin with IC50 values from 0.3 nM to 8.4 nM, confirming this family as highly potent protease inhibitors.

## Key findings

  • Native metabolomics screening of eight cyanobacterial extracts found six putative trypsin binders in *Nostoc* sp. KVJ20, with averaged mass shifts of Δm/z 979.4765, 1007.7051, 1007.9610, 1048.4770, 1077.8262, and 1106.0389.
  • Two of the binders were new suomilide analogs: suomilide G (1; C41H66N8O19S) and suomilide H (2; C47H76N8O20S).
  • The isolated compounds inhibited trypsin in a fluorescence-based assay with IC50 values of 0.3 nM ± 0.05 (suomilide B), 8.4 nM ± 0.58 (suomilide D), 0.7 nM ± 0.05 (suomilide G), and 1.4 nM ± 0.14 (suomilide H).
  • The paper states that suomilides B, D, G, and H inhibit trypsin in the low nanomolar to high picomolar range, and that suomilide B was the strongest inhibitor among those tested.

## Methods

  • The study used native metabolomics with porcine trypsin to screen whole cyanobacterial metabolomes; the native runs were paired with conventional metabolomics runs without protein to match retention times and enable dereplication/prioritization.
  • Eight cyanobacterial strains were screened; the hit extract from *Nostoc* sp. KVJ20 was fractionated and purified by reversed-phase flash chromatography and preparative HPLC to isolate the suomilides.
  • Structures were solved using HR-ESI-MS, 1D/2D NMR, Marfey’s amino acid analysis, and bioinformatic/biosynthetic considerations; bioactivity was confirmed with a fluorescence-based trypsin inhibition assay and kinetic measurements in triplicate.

## Limitations

  • The paper states that native metabolomics has limited throughput for buffer-exchanged trypsin extracts because of trypsin autolysis, which restricts screening capacity.
  • The absolute configuration of the galactose in compound 1 could not be determined because of the limited amount of compound; this limitation is stated in the paper.
  • The absolute configurations of compound 2 are inferred by biosynthetic logic rather than directly proven, and the absolute configuration of the C-2/azabicyclononane moiety in 1 remains unresolved; these are evident from the text.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1021/acs.jnatprod.5c01380

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

1 Native metabolomics workflow for discovering trypsin inhibitors. Cyanobacterial extracts are initially separated using μ-flow UHPLC. After the column, the eluent’s pH is adjusted with an excess of NH4Ac solution via a makeup pump to simulate native-like conditions. Simultaneously, trypsin is continuously infused in NH4Ac solution via a syringe pump. The resulting protein or protein-small molecule complexes are analyzed using native MS conditions. Concurrently, a separate metabolomics run is conducted, featuring UHPLC-HR-MS/MS acquisition without the infusion of protein to enable correlation of retention times and MS1 level data of the two runs. Created in BioRender. Reher, R. (2026) https://BioRender.com/2jhyps4.
1 Native metabolomics workflow for discovering trypsin inhibitors. Cyanobacterial extracts are initially separated using μ-flow UHPLC. After the column, the eluent’s pH is adjusted with an excess of NH4Ac solution via a makeup pump to simulate native-like conditions. Simultaneously, trypsin is continuously infused in NH4Ac solution via a syringe pump. The resulting protein or protein-small molecule complexes are analyzed using native MS conditions. Concurrently, a separate metabolomics run is conducted, featuring UHPLC-HR-MS/MS acquisition without the infusion of protein to enable correlation of retention times and MS1 level data of the two runs. Created in BioRender. Reher, R. (2026) https://BioRender.com/2jhyps4.CC BY · PubMed Central
2 Native metabolomics analysis of trypsin versus Nostoc sp. KVJ20 extract. (A) Direct infusion native mass spectrometry measurement of trypsin. (B) Direct infusion native mass spectrometry measurements of protein-inhibitor interactions. Positive control with the confirmed benzamidine-based trypsin inhibitor BAPA (m/z 557.2646). The gray circle indicates mass shifts corresponding to the trypsin-BAPA complex. (C) Low m/z range to detect the nonbinding portion of BAPA. (D) Native metabolomics run at retention time (RT) 3.86–4.21 min. Mass shift of binder 1 (Δm/z 979.4765) binding to trypsin in light turquoise. (E) Native metabolomics run at RT 5.09–5.62 min. Mass shift of binder 2 (Δm/z 1007.7051) in turquoise. (F) Native metabolomics run at RT 5.80–6.15 min. Mass shift of isomeric binder 3 (Δm/z 1007.9610, compound 1) in teal. (G) Native metabolomics run at RT 6.33–6.50 min. Mass shift of binder 4 (Δm/z 1048.4770) in dark teal. (H) Native metabolomics run at RT 7.74–7.91 min. Mass shift of binder 5 (Δm/z 1077.8262) in petrol green. (I) Native metabolomics run at RT 8.97–9.32 min. Mass shift of binder 6 (Δm/z 1106.0389, compound 2) in dark petrol green. (J) Base peak chromatogram (BPC) of the subsequent metabolomics run of the extract of Nostoc sp. KVJ20. Extracted ion chromatograms of the m/z 979.3921, m/z 1007.4223, m/z 1007.4234 (compound 1), m/z 1049.4344, m/z 1077.4643, m/z 1105.4956 (compound 2). For correlation of native metabolomics and metabolomics runs, please refer to Table S1.
2 Native metabolomics analysis of trypsin versus Nostoc sp. KVJ20 extract. (A) Direct infusion native mass spectrometry measurement of trypsin. (B) Direct infusion native mass spectrometry measurements of protein-inhibitor interactions. Positive control with the confirmed benzamidine-based trypsin inhibitor BAPA (m/z 557.2646). The gray circle indicates mass shifts corresponding to the trypsin-BAPA complex. (C) Low m/z range to detect the nonbinding portion of BAPA. (D) Native metabolomics run at retention time (RT) 3.86–4.21 min. Mass shift of binder 1 (Δm/z 979.4765) binding to trypsin in light turquoise. (E) Native metabolomics run at RT 5.09–5.62 min. Mass shift of binder 2 (Δm/z 1007.7051) in turquoise. (F) Native metabolomics run at RT 5.80–6.15 min. Mass shift of isomeric binder 3 (Δm/z 1007.9610, compound 1) in teal. (G) Native metabolomics run at RT 6.33–6.50 min. Mass shift of binder 4 (Δm/z 1048.4770) in dark teal. (H) Native metabolomics run at RT 7.74–7.91 min. Mass shift of binder 5 (Δm/z 1077.8262) in petrol green. (I) Native metabolomics run at RT 8.97–9.32 min. Mass shift of binder 6 (Δm/z 1106.0389, compound 2) in dark petrol green. (J) Base peak chromatogram (BPC) of the subsequent metabolomics run of the extract of Nostoc sp. KVJ20. Extracted ion chromatograms of the m/z 979.3921, m/z 1007.4223, m/z 1007.4234 (compound 1), m/z 1049.4344, m/z 1077.4643, m/z 1105.4956 (compound 2). For correlation of native metabolomics and metabolomics runs, please refer to Table S1.CC BY · PubMed Central
3 Feature-based molecular network of a LC-HR-MS/MS data set of Nostoc sp. KVJ20 with tailored MassQL queries for the native metabolomics derived trypsin binders. We chose the MS2 fragments that all the binders had in common, with m/z values of 188.128, 155.129, and 109.029, nodes highlighted in cyan with the binders, detected via native metabolomics highlighted in orange. The m/z tolerance was set at 0.005 Da and the minimum intensity percentage of 5% compared to the MS2 base peak. The structures of compounds 1 and 2 were unknown but suspected to be suomilide congeners due to their clustering with known suomilides, shared MS/MS fragments, a characteristic sulfate loss during LC-MS measurement (Figure S3), and trypsin binding in native metabolomics.
3 Feature-based molecular network of a LC-HR-MS/MS data set of Nostoc sp. KVJ20 with tailored MassQL queries for the native metabolomics derived trypsin binders. We chose the MS2 fragments that all the binders had in common, with m/z values of 188.128, 155.129, and 109.029, nodes highlighted in cyan with the binders, detected via native metabolomics highlighted in orange. The m/z tolerance was set at 0.005 Da and the minimum intensity percentage of 5% compared to the MS2 base peak. The structures of compounds 1 and 2 were unknown but suspected to be suomilide congeners due to their clustering with known suomilides, shared MS/MS fragments, a characteristic sulfate loss during LC-MS measurement (Figure S3), and trypsin binding in native metabolomics.CC BY · PubMed Central
4 Structures of the new analogs suomilide G (1) and suomilide H (2) together with the known congeners suomilide B (3) and D (4). The yet undefined stereochemistry of 3 and 4 was adapted based on analogy and biosynthetic logic.
4 Structures of the new analogs suomilide G (1) and suomilide H (2) together with the known congeners suomilide B (3) and D (4). The yet undefined stereochemistry of 3 and 4 was adapted based on analogy and biosynthetic logic.CC BY · PubMed Central
5 Biosynthetic gene cluster of Nostoc sp. KVJ20 for banyaside and suomilide like molecules (bsl) as well as the proposed pathway for the biosynthesis of 1 and 2. OMT = O-methyl transferase; FkbH = FkbH-like domain; PCP = peptidyl-carrier protein domain; ST = sulfotransferase; C = condensation domain; A = adenylation domain; E = epimerization domain; MBOAT = membrane bound O-acyl transferase; PT = prenyltransferase; RO = Rieske oxygenase; GT = glycosyltransferase; 1,3-BPG = 1,3-bisphosphoglycerate; Agma = agmatine; Abn = azabicyclononane; Ile = isoleucine; Aaep = 1-amidino-3-(2-aminoethyl)-3-pyrroline (Aaep).
5 Biosynthetic gene cluster of Nostoc sp. KVJ20 for banyaside and suomilide like molecules (bsl) as well as the proposed pathway for the biosynthesis of 1 and 2. OMT = O-methyl transferase; FkbH = FkbH-like domain; PCP = peptidyl-carrier protein domain; ST = sulfotransferase; C = condensation domain; A = adenylation domain; E = epimerization domain; MBOAT = membrane bound O-acyl transferase; PT = prenyltransferase; RO = Rieske oxygenase; GT = glycosyltransferase; 1,3-BPG = 1,3-bisphosphoglycerate; Agma = agmatine; Abn = azabicyclononane; Ile = isoleucine; Aaep = 1-amidino-3-(2-aminoethyl)-3-pyrroline (Aaep).CC BY · PubMed Central
6 Inhibition of trypsin (100 pM in the assay) by suomilides. (A) Biphasic progress curves were observed for all compounds, as exemplified by the inhibition of trypsin by suomilide B (Table S4). (B) Determination of the IC50 values for the four suomilides. The measurements were performed in the presence of N-p-Tosyl-Gly-Pro-Arg-AMC (4.0 μM, K M = 12 μM). The measured data (n = 3) were fitted to the 4-parameter logistic model. For better comparison between the different measurements, the velocity, determined as relative fluorescence units (RFU)/sec, was converted into percentage activity (Table S5).
6 Inhibition of trypsin (100 pM in the assay) by suomilides. (A) Biphasic progress curves were observed for all compounds, as exemplified by the inhibition of trypsin by suomilide B (Table S4). (B) Determination of the IC50 values for the four suomilides. The measurements were performed in the presence of N-p-Tosyl-Gly-Pro-Arg-AMC (4.0 μM, K M = 12 μM). The measured data (n = 3) were fitted to the 4-parameter logistic model. For better comparison between the different measurements, the velocity, determined as relative fluorescence units (RFU)/sec, was converted into percentage activity (Table S5).CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 1 Not valid · 1 Not checked · 43 Own results and interpretations

25 more claims

Create a free account to see all 45 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 12
  • Probably not a substantial claim. 3

Create a free account to see these claims.

Citations

Cites

Cited by

See all 1

Metadata

Authors
Naimi, A., Ulbricht, C., Trinh, T. L., Kehraus, S., Dreckmann, T. M., Linne, U., Hardes, K., Reher, R., & Baunach, M.
Affiliations
  • Philipps University of Marburg (DE)
  • University of Bonn (DE)
  • Fraunhofer Institute for Molecular Biology and Applied Ecology (DE)
Corresponding author
  • Reher, Raphael
  • Baunach, Martin
Venue
Journal of Natural Products
Published
2026-04-01
Volume
89
Issue
4
Pages
1148-1160
ISSN
  • 0163-3864 (ISSN-L)
  • 1520-6025
OpenAlex
W7147127043
Cited by
1
References
65
Citations by year
2026: 1
FWCI
4.21
Type
journal article
Language
en
Open access
Locations
  • Journal of Natural Products (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Fonds der Chemischen Industrie
  • Germany's Joint Federal and State Program Supporting Early-Career Researchers
Topics
  • Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Bioactive natural compounds
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Marine Sponges and Natural Products
Keywords
trypsin inhibitor, serine protease inhibitors, cyanobacteria, Nostoc, natural product discovery, competitive inhibition, structure elucidation
MeSH terms
Trypsin Inhibitors, Molecular Structure, Nuclear Magnetic Resonance, Biomolecular, Nostoc, Metabolomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.